{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:49:34Z","timestamp":1794743374864,"version":"4.9.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2A-r) represents a highly aggressive and prognostically unfavorable subtype of leukemia, often resistant to standard treatments and associated with high relapse rates. KMT2A-r, found in 3\u201310% of adult AML cases, disrupt epigenetic regulation by forming chimeric proteins that activate oncogenic pathways like HOXA and MEIS1. These fusion proteins recruit cofactors such as Menin and DOT1L, driving leukemogenesis through abnormal histone methylation. Diagnosing KMT2A-r AML requires precision, with traditional methods like FISH and RT-PCR being complemented by advanced technologies such as next-generation sequencing (NGS) and machine learning (ML). ML models, leveraging transcriptomic data, can predict KMT2A-r and identify biomarkers like LAMP5 and SKIDA1, improving risk stratification. Therapeutically, there is a shift from chemotherapy to targeted therapies. Menin inhibitors (e.g., Revumenib, Ziftomenib) disrupt the Menin-KMT2A interaction, suppressing HOXA\/MEIS1 and promoting differentiation. DOT1L inhibitors (e.g., Pinometostat) show promise in combination therapies, while novel approaches like WDR5 inhibitors and PROTAC-mediated degradation are expanding treatment options. Despite progress, challenges remain, including optimizing minimal residual disease monitoring, overcoming resistance, and validating biomarkers. This review emphasizes the imperative to translate molecular insights into personalized therapeutic regimens, offering renewed hope for patients afflicted by this historically refractory malignancy.<\/jats:p>","DOI":"10.1186\/s40364-025-00786-y","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:09:45Z","timestamp":1747166985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5998-1722","authenticated-orcid":false,"given":"Sara","family":"Zehtabcheh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-8271","authenticated-orcid":false,"given":"Marjan","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Zabihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-3222","authenticated-orcid":false,"given":"Sahar","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4884-5218","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"7","key":"786_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"11","key":"786_CR2","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol. 2022;140(11):1200\u201328.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"786_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, Tayefeh S, Mohammadi MH, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"12","key":"786_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/cncr.34728","volume":"129","author":"D Nguyen","year":"2023","unstructured":"Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, et al. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023;129(12):1856\u201365.","journal-title":"Cancer"},{"issue":"12","key":"786_CR5","first-page":"1345","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. J Am Soc Hematol. 2022;140(12):1345\u201377.","journal-title":"J Am Soc Hematol"},{"issue":"10","key":"786_CR6","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1080\/10428194.2021.1919663","volume":"62","author":"N Wang","year":"2021","unstructured":"Wang N, Yuan L, Jing Y, Fan K, Jin H, Lv C, et al. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations. Leuk Lymphoma. 2021;62(10):2466\u201374.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"786_CR7","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.3390\/ijms25169023","volume":"25","author":"L Guarnera","year":"2024","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024;25(16):9023.","journal-title":"Int J Mol Sci"},{"key":"786_CR8","first-page":"4","volume":"5","author":"AC Winters","year":"2017","unstructured":"Winters AC, Bernt KM. MLL-Rearranged Leukemias-An update on science and clinical approaches. Front Pead. 2017;5:4.","journal-title":"Front Pead"},{"issue":"5","key":"786_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","volume":"112","author":"J Min","year":"2003","unstructured":"Min J, Feng Q, Li Z, Zhang Y, Xu RM. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell. 2003;112(5):711\u201323.","journal-title":"Cell"},{"issue":"7954","key":"786_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"key":"786_CR11","doi-asserted-by":"crossref","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024;25(16).","DOI":"10.3390\/ijms25169023"},{"issue":"5","key":"786_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37(5):988\u20131005.","journal-title":"Leukemia"},{"issue":"12","key":"786_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nrm3230","volume":"12","author":"B Schuettengruber","year":"2011","unstructured":"Schuettengruber B, Martinez A-M, Iovino N, Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol. 2011;12(12):799\u2013814.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"786_CR14","doi-asserted-by":"crossref","unstructured":"Ogino J, Dou Y. Histone methyltransferase KMT2A: developmental regulation to oncogenic transformation. J Biol Chem. 2024:107791.","DOI":"10.1016\/j.jbc.2024.107791"},{"issue":"6","key":"786_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015;15(6):334\u201346.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"786_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0092-8674(92)90602-9","volume":"71","author":"DC Tkachuk","year":"1992","unstructured":"Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71(4):691\u2013700.","journal-title":"Cell"},{"issue":"1","key":"786_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1128\/MCB.23.1.186-194.2003","volume":"23","author":"JJ Hsieh","year":"2003","unstructured":"Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol. 2003;23(1):186\u201394.","journal-title":"Mol Cell Biol"},{"issue":"15","key":"786_CR18","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1158\/0008-5472.CAN-07-6514","volume":"68","author":"J Chen","year":"2008","unstructured":"Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman MJ, et al. Loss of MLL PHD finger 3 is necessary for MLL-ENL\u2013induced hematopoietic stem cell immortalization. Cancer Res. 2008;68(15):6199\u2013207.","journal-title":"Cancer Res"},{"issue":"5","key":"786_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1097-2765(02)00741-4","volume":"10","author":"TA Milne","year":"2002","unstructured":"Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, et al. MLL targets SET domain methyltransferase activity to hox gene promoters. Mol Cell. 2002;10(5):1107\u201317.","journal-title":"Mol Cell"},{"issue":"3","key":"786_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.stem.2007.05.019","volume":"1","author":"CD Jude","year":"2007","unstructured":"Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007;1(3):324\u201337.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"786_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1101\/gad.1898410","volume":"24","author":"M Mohan","year":"2010","unstructured":"Mohan M, Herz H-M, Takahashi Y-H, Lin C, Lai KC, Zhang Y, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24(6):574\u201389.","journal-title":"Genes Dev"},{"issue":"4","key":"786_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/00062752-200207000-00004","volume":"9","author":"P Ernst","year":"2002","unstructured":"Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9(4):282\u20137.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"786_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ccr.2008.03.005","volume":"13","author":"W Chen","year":"2008","unstructured":"Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5):432\u201340.","journal-title":"Cancer Cell"},{"issue":"1","key":"786_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-021-01057-7","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Song Y. Structure, function and Inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021;14(1):56.","journal-title":"J Hematol Oncol"},{"key":"786_CR25","doi-asserted-by":"crossref","unstructured":"Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 2022;15.","DOI":"10.1186\/s13045-022-01251-1"},{"issue":"1","key":"786_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, Soleimani Samarkhazan H, Nouri S, Khaksari MN, Abbasi Sourki P, Sargazi Aval O, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Experimental Med. 2025;25(1):73.","journal-title":"Clin Experimental Med"},{"issue":"8","key":"786_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.leukres.2011.03.015","volume":"35","author":"P Menendez","year":"2011","unstructured":"Menendez P, Bueno C. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get? Leuk Res. 2011;35(8):989\u201390.","journal-title":"Leuk Res"},{"key":"786_CR28","doi-asserted-by":"crossref","unstructured":"Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. 1996.","DOI":"10.1182\/blood.V87.3.1123.bloodjournal8731123"},{"issue":"3","key":"786_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/leu.2017.294","volume":"32","author":"C Prieto","year":"2018","unstructured":"Prieto C, L\u00f3pez-Mill\u00e1n B, Roca-Ho H, Stam R, Romero-Moya D, Rodr\u00edguez-Baena F, et al. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia. 2018;32(3):633\u201344.","journal-title":"Leukemia"},{"issue":"8","key":"786_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2008.134","volume":"22","author":"C Bueno","year":"2008","unstructured":"Bueno C, Montes R, Martin L, Prat I, Hernandez M, Orfao A, et al. NG2 antigen is expressed in CD34\u2009+\u2009HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia. 2008;22(8):1475\u20138.","journal-title":"Leukemia"},{"issue":"7","key":"786_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/sj.leu.2401840","volume":"14","author":"C Wuchter","year":"2000","unstructured":"Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia. 2000;14(7):1232\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"786_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, Ebrahimdoost M, Mohammadi SA, Soleimani Samarkhazan H, Khamisipour G, Aghaei M. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"key":"786_CR33","doi-asserted-by":"crossref","unstructured":"Fenton M, Gasparetto M, Hong C-S, Wang X, Smith C, Whiteside T, et al. Identification of chondroitin sulfate Proteoglycan-4 in acute myeloid leukemia using monoclonal antibody 225.28. American Society of Hematology; 2011.","DOI":"10.1182\/blood.V118.21.4885.4885"},{"issue":"2","key":"786_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3727\/096504014X14174484758503","volume":"22","author":"M Fenton","year":"2015","unstructured":"Fenton M, Whiteside TL, Ferrone S, Boyiadzis M. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res. 2015;22(2):117.","journal-title":"Oncol Res"},{"issue":"2","key":"786_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2141.2010.08459.x","volume":"152","author":"R Marschalek","year":"2011","unstructured":"Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011;152(2):141\u201354.","journal-title":"Br J Haematol"},{"issue":"3","key":"786_CR36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/gcc.20082","volume":"41","author":"KE Barber","year":"2004","unstructured":"Barber KE, Ford AM, Harris RL, Harrison CJ, Moorman AV. MLL translocations with concurrent 3\u2032 deletions: interpretation of FISH results. Genes Chromosom Cancer. 2004;41(3):266\u201371.","journal-title":"Genes Chromosom Cancer"},{"issue":"9","key":"786_CR37","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41375-019-0451-7","volume":"33","author":"C Meyer","year":"2019","unstructured":"Meyer C, Lopes BA, Caye-Eude A, Cav\u00e9 H, Arfeuille C, Cuccuini W, et al. Human MLL\/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL\u2013USP2 fusions. Leukemia. 2019;33(9):2306\u201340.","journal-title":"Leukemia"},{"key":"786_CR38","doi-asserted-by":"crossref","unstructured":"Meyer C, Marschalek R. LDI-PCR: identification of known and unknown gene fusions of the human MLL gene. Leukemia: Methods Protocols. 2009:71\u201383.","DOI":"10.1007\/978-1-59745-418-6_5"},{"issue":"2","key":"786_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1073\/pnas.0406994102","volume":"102","author":"C Meyer","year":"2005","unstructured":"Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci. 2005;102(2):449\u201354.","journal-title":"Proc Natl Acad Sci"},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cancergen.2023.07.003","volume":"276","author":"Y Kim","year":"2023","unstructured":"Kim Y, Kim B, Seong M-W, Lee DS, Hong KT, Kang HJ, et al. Cryptic KMT2A\/MLLT10 fusion detected by next-generation sequencing in a case of pediatric acute megakaryoblastic leukemia. Cancer Genet. 2023;276:36\u20139.","journal-title":"Cancer Genet"},{"issue":"5","key":"786_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/bloodadvances.2019001008","volume":"4","author":"LM Brown","year":"2020","unstructured":"Brown LM, Lonsdale A, Zhu A, Davidson NM, Schmidt B, Hawkins A, et al. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. Blood Adv. 2020;4(5):930\u201342.","journal-title":"Blood Adv"},{"issue":"20","key":"786_CR42","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1182\/bloodadvances.2019000404","volume":"3","author":"N Shiba","year":"2019","unstructured":"Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. Blood Adv. 2019;3(20):3157\u201369.","journal-title":"Blood Adv"},{"key":"786_CR43","doi-asserted-by":"publisher","first-page":"749472","DOI":"10.3389\/fphar.2022.749472","volume":"13","author":"BA Lopes","year":"2022","unstructured":"Lopes BA, Poubel CP, Teixeira CE, Caye-Eude A, Cav\u00e9 H, Meyer C, et al. Novel diagnostic and therapeutic options for KMT2A-rearranged acute leukemias. Front Pharmacol. 2022;13:749472.","journal-title":"Front Pharmacol"},{"issue":"1","key":"786_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-022-01251-1","volume":"15","author":"Y Yi","year":"2022","unstructured":"Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 2022;15(1):35.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"786_CR45","first-page":"1017","volume":"122","author":"SR Daigle","year":"2013","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent Inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood J Am Soc Hematol. 2013;122(6):1017\u201325.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"786_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","volume":"20","author":"SR Daigle","year":"2011","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53\u201365.","journal-title":"Cancer Cell"},{"issue":"22","key":"786_CR47","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","volume":"128","author":"N Shukla","year":"2016","unstructured":"Shukla N, Wetmore C, O\u2019Brien MM, Silverman LB, Brown P, Cooper TM, et al. Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia. Blood. 2016;128(22):2780.","journal-title":"Blood"},{"issue":"7","key":"786_CR48","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/cancers12071972","volume":"12","author":"A Lonetti","year":"2020","unstructured":"Lonetti A, Indio V, Laginestra MA, Tarantino G, Chiarini F, Astolfi A, et al. Inhibition of methyltransferase DOT1L sensitizes to Sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML. Cancers. 2020;12(7):1972.","journal-title":"Cancers"},{"key":"786_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01057-7","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Song Y. Structure, function and Inhibition of critical protein\u2013protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021;14:1\u201333.","journal-title":"J Hematol Oncol"},{"issue":"52","key":"786_CR50","doi-asserted-by":"publisher","first-page":"40690","DOI":"10.1074\/jbc.M110.172783","volume":"285","author":"J Grembecka","year":"2010","unstructured":"Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem. 2010;285(52):40690\u20138.","journal-title":"J Biol Chem"},{"issue":"15","key":"786_CR51","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","volume":"67","author":"C Caslini","year":"2007","unstructured":"Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with Menin is required for transformation. Cancer Res. 2007;67(15):7275\u201383.","journal-title":"Cancer Res"},{"issue":"4","key":"786_CR52","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4155\/fmc.13.214","volume":"6","author":"T Cierpicki","year":"2014","unstructured":"Cierpicki T, Grembecka J. Challenges and opportunities in targeting the menin\u2013MLL interaction. Future Med Chem. 2014;6(4):447\u201362.","journal-title":"Future Med Chem"},{"issue":"2","key":"786_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The Menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207\u201318.","journal-title":"Cell"},{"issue":"4","key":"786_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","volume":"27","author":"D Borkin","year":"2015","unstructured":"Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic Inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27(4):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"6","key":"786_CR55","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, et al. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36(6):660\u201373. e11.","journal-title":"Cancer Cell"},{"issue":"2","key":"786_CR56","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Investig. 2020;130(2):981\u201397.","journal-title":"J Clin Investig"},{"key":"786_CR57","unstructured":"Mullard A. FDA approves first Menin inhibitor, for acute leukaemia. Nature reviews Drug discovery."},{"key":"786_CR58","doi-asserted-by":"publisher","first-page":"203636132311837","DOI":"10.1177\/20363613231183785","volume":"15","author":"A Fareed","year":"2023","unstructured":"Fareed A, Inam N, Faraz F. Breakthrough treatment choice for acute myeloid leukemia in pediatric and adult patients: revumenib, an oral selective inhibitor of KMTA2Ar. Rare Tumors. 2023;15:20363613231183785.","journal-title":"Rare Tumors"},{"key":"786_CR59","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2023-189762","volume":"142","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Issa GC, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemias: efficacy and safety results from the Augment-101 phase 1\/2 study. Blood. 2023;142:2907.","journal-title":"Blood"},{"key":"786_CR60","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1182\/blood-2023-189036","volume":"142","author":"A Zucenka","year":"2023","unstructured":"Zucenka A, Issa GC, Arellano M, Khazal S, Khera N, Stock W, et al. Revumenib maintenance therapy following revumenib-induced remission and transplant. Blood. 2023;142:4950.","journal-title":"Blood"},{"issue":"Supplement 1","key":"786_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1182\/blood-2022-167412","volume":"140","author":"HP Erba","year":"2022","unstructured":"Erba HP, Fathi AT, Issa GC, Altman JK, Montesinos P, Patnaik MM, et al. Update on a phase 1\/2 first-in-human study of the menin-KMT2A (MLL) inhibitor Ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):153\u20136.","journal-title":"Blood"},{"issue":"10","key":"786_CR62","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","volume":"108","author":"J Rausch","year":"2023","unstructured":"Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, et al. Menin inhibitor Ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023;108(10):2837.","journal-title":"Haematologica"},{"key":"786_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood-2023-172422","volume":"142","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Searle E, Abdul-Hay M, Abedin S, Aldoss I, Pi\u00e9rola AA, et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;142:57.","journal-title":"Blood"},{"issue":"Supplement 1","key":"786_CR64","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2022-167205","volume":"140","author":"V Ciaurro","year":"2022","unstructured":"Ciaurro V, Skwarska A, Daver N, Konopleva M. Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in AML cells with MLL-Rearranged and NPM1 mutation. Blood. 2022;140(Supplement 1):3082\u20133.","journal-title":"Blood"},{"issue":"3","key":"786_CR65","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M. Effect of Harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramedical Sci Military Health. 2016;11(3):28\u201333.","journal-title":"Paramedical Sci Military Health"},{"issue":"1","key":"786_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","volume":"23","author":"M Numata","year":"2023","unstructured":"Numata M, Haginoya N, Shiroishi M, Hirata T, Sato-Otsubo A, Yoshikawa K, et al. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023;23(1):36.","journal-title":"Cancer Cell Int"},{"key":"786_CR67","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/blood-2023-173149","volume":"142","author":"J Lancet","year":"2023","unstructured":"Lancet J, Ravandi F, Montesinos P, Barrientos JC, Badar T, Alegre A, et al. Covalent Menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study. Blood. 2023;142:2916.","journal-title":"Blood"},{"issue":"9","key":"786_CR68","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of Menin Inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395.","journal-title":"Leukemia"},{"issue":"2","key":"786_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccr.2009.12.034","volume":"17","author":"AT Thiel","year":"2010","unstructured":"Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell. 2010;17(2):148\u201359.","journal-title":"Cancer Cell"},{"issue":"2","key":"786_CR70","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.molcel.2013.12.001","volume":"53","author":"F Cao","year":"2014","unstructured":"Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 2014;53(2):247\u201361.","journal-title":"Mol Cell"},{"issue":"24","key":"786_CR71","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/s41388-022-02340-8","volume":"41","author":"D Li","year":"2022","unstructured":"Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, et al. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022;41(24):3328\u201340.","journal-title":"Oncogene"},{"issue":"1","key":"786_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-26890-9","volume":"13","author":"Z Gou","year":"2023","unstructured":"Gou Z, Li Y. Prisoner\u2019s dilemma game model based on historical strategy information. Sci Rep. 2023;13(1):1.","journal-title":"Sci Rep"},{"issue":"7","key":"786_CR73","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2008.002436","volume":"94","author":"RK Slany","year":"2009","unstructured":"Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984\u201393.","journal-title":"Haematologica"},{"key":"786_CR74","doi-asserted-by":"crossref","unstructured":"Perner F, Gadrey JY, Armstrong SA, K\u00fchn MWM. Targeting the Menin-KMT2A interaction in leukemia: lessons learned and future directions. Int J Cancer. 2025.","DOI":"10.1002\/ijc.35332"},{"key":"786_CR75","doi-asserted-by":"publisher","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang J, Zhang F, Liu P. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol. 2023;14:1151032.","journal-title":"Front Pharmacol"},{"key":"786_CR76","doi-asserted-by":"crossref","unstructured":"Cantilena S, AlAmeri M, Che N, Williams O, de Boer J. Synergistic strategies for KMT2A-Rearranged leukemias: beyond Menin inhibitor. Cancers. 2024;16(23).","DOI":"10.3390\/cancers16234017"},{"issue":"1","key":"786_CR77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin Inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384.","journal-title":"J Clin Oncol"},{"key":"786_CR78","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, et al. Phase I\/II study of the All-Oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML. Blood. 2024;144:216.","journal-title":"Blood"},{"key":"786_CR79","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1182\/blood-2024-208887","volume":"144","author":"W Bourgeois","year":"2024","unstructured":"Bourgeois W, Cutler J, Rice HE, Regalado B, Wenge DV, Perner F, et al. Discerning the landscape of Menin inhibitor resistance. Blood. 2024;144:724.","journal-title":"Blood"},{"issue":"7954","key":"786_CR80","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to Menin Inhibition. Nature. 2023;615(7954):913\u20139.","journal-title":"Nature"},{"issue":"5","key":"786_CR81","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/hem.V20.5.2023510","volume":"20","author":"CM McMahon","year":"2023","unstructured":"McMahon CM. MEN1 mutations induce acquired resistance to the Menin inhibitor revumenib. Hematologist. 2023;20(5):913\u20139.","journal-title":"Hematologist"},{"issue":"1","key":"786_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","volume":"13","author":"W Fiskus","year":"2023","unstructured":"Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood cancer J. 2023;13(1):53.","journal-title":"Blood cancer J"},{"issue":"23","key":"786_CR83","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers16234017","volume":"16","author":"S Cantilena","year":"2024","unstructured":"Cantilena S, AlAmeri M, Che N, Williams O, de Boer J. Synergistic strategies for KMT2A-Rearranged leukemias: beyond Menin inhibitor. Cancers. 2024;16(23):4017.","journal-title":"Cancers"},{"issue":"11","key":"786_CR84","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood.2024025760","volume":"144","author":"CA Heckman","year":"2024","unstructured":"Heckman CA. A menin-KMT2A inhibitor to overcome resistance. Blood. 2024;144(11):1139\u201340.","journal-title":"Blood"},{"key":"786_CR85","unstructured":"A Phase 1\/2, Label O. Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04109482"},{"issue":"1","key":"786_CR86","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, Taheri F, Jafari Khouzani P, Rahmani E, Tavakoli R, Moghadam Fard A, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00786-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:03:39Z","timestamp":1747209819000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00786-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00786-y","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}